DYMELOR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYMELOR is an oral small-molecule tablet approved by Eli Lilly in 1964 for an undisclosed indication. The specific mechanism of action and therapeutic class are not documented in available data, limiting clinical assessment.
LOE Approaching
With LOE approaching and minimal linked job activity, this legacy brand is in wind-down mode with contracted team size and defensive commercial focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DYMELOR offers very limited career growth potential with zero linked job openings and an approaching loss-of-exclusivity timeline. Roles on this product typically focus on defensive commercial strategy and regulatory maintenance rather than innovation or expansion.
Brand Manager (Defensive)Field Sales (Legacy)
Worked on DYMELOR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.